Myriad Genetics, Inc.

NASDAQ:MYGN  
27.60
+0.90 (+3.37%)
Other Pre-Announcement

Myriad Genetics Reports Q2 Revenue Rose 7%

Published: 08/04/2022 11:48 GMT
Myriad Genetics, Inc. (MYGN) - Myriad Genetics Reports Second Quarter Financial Results.
Q2 Revenue Rose 7 Percent to $179.3 Million.
Q2 Adjusted Earnings per Share $0.04.
Q2 GAAP Loss per Share $0.18.
Q2 Earnings per Share View $0.01, Revenue View $171.0 Million -- Refinitiv Ibes Data (analyst estimates).
Reiterates FY 2022 Revenue and Gross Margin Guidance and Updates Its Guidance for Total Operating Expense and Eps.